hydrochlorothiazide trial summary

All type of patients: 2 trials - Nordrehaug - Sievert

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
hospitalisation for cardiovascular causes	no data
death from cardiovascular causes or hospitalization for cardiovascular causes	no data
serious hyperkalemia	no data
Sudden death	no data
death from cardiovascular causes or hospitalization for heart failure	no data
Death from any cause or hospitalization for any reason	no data
exacerbation of heart failure	no data
NYHA class improvement	0.06 [0.01 0.49]	p=0.04	0	58	1	Nordrehaug,
Death from any cause or hospitalization for heart failure	no data
Cardiovascular death	no data
hospitalisation for heart failure	no data
All cause death	no data
Hospitalization for any reason	no data
Adverse events leading to treatment discontinuation	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
hospitalisation for cardiovascular causes	no data
death from cardiovascular causes or hospitalization for cardiovascular causes	no data
serious hyperkalemia	no data
Sudden death	no data
death from cardiovascular causes or hospitalization for heart failure	no data
Death from any cause or hospitalization for any reason	no data
exacerbation of heart failure	no data
NYHA class improvement	no data
Death from any cause or hospitalization for heart failure	no data
Cardiovascular death	no data
hospitalisation for heart failure	no data
All cause death	no data
Hospitalization for any reason	no data
Adverse events leading to treatment discontinuation	no data
Adverse events	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patient: 2 trials - Kuramoto - EWPHE

No demonstrated result

suggested cardiovascular events by 29% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.71 [0.51 1.00]	p=0.04	0	931	2	Kuramoto,EWPHE,
Cardiovascular death	0.75 [0.53 1.05]	p=1.00	0	931	2	Kuramoto,EWPHE,
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	0.69 [0.44 1.08]	p=1.00	0	931	2	Kuramoto,EWPHE,
Coronary event	0.82 [0.55 1.22]	p=1.00	0	931	2	Kuramoto,EWPHE,
Heart failure	0.78 [0.43 1.44]	p=1.00	0	931	2	Kuramoto,EWPHE,
All cause death	0.93 [0.71 1.23]	p=1.00	0	931	2	Kuramoto,EWPHE,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Uncomplicated hypertension: 2 trials - Kuramoto - EWPHE

No demonstrated result

suggested cardiovascular events by 29% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
cardiovascular events	0.71 [0.51 1.00]	p=0.04	0	931	2	Kuramoto,EWPHE,
Cardiovascular death	0.75 [0.53 1.05]	p=1.00	0	931	2	Kuramoto,EWPHE,
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	0.69 [0.44 1.08]	p=1.00	0	931	2	Kuramoto,EWPHE,
Coronary event	0.82 [0.55 1.22]	p=1.00	0	931	2	Kuramoto,EWPHE,
Heart failure	0.78 [0.43 1.44]	p=1.00	0	931	2	Kuramoto,EWPHE,
All cause death	0.93 [0.71 1.23]	p=1.00	0	931	2	Kuramoto,EWPHE,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Very ederly (80 and more): 1 trials - EWPHE (subgroup )

No demonstrated result

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Hydrochlorothiazide diuretics